Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]
Continue reading …Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod
September 30, 2017 No Comment
Abemaciclib FDA approval : Eli Lilly and Company (Lilly) has secured the US FDA approval for Verzenio (abemaciclib) to treat metastatic breast cancer in patients whose disease had progressed after a prior treatment. Abemaciclib FDA Approval The breast cancer drug approval is for patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 […]
Continue reading …
Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]
Continue reading …
Business News Today
- ICAP and Charter Realty & Development acquire Baederwood Shoppes
- Superior Plus acquires Western Propane Service in Southern California
- OALP round 4 results : ONGC wins all seven oil and gas blocks
- Johan Sverdrup oil field inaugurated by Norwegian PM Erna Solberg
- Carmell Therapeutics gets IND clearance for CT-101 bone healing accelerant
- KKR acquires Riata Corporate Park in Austin for $258m
- Medical Mutual to acquire wellness plan provider Bravo
- Apache, Total pull off Maka Central discovery in offshore Suriname Block 58
- ATAI Life Sciences partners with Neuronasal to develop concussion treatment
- US specialty food producer Stonewall Kitchen to launch multiple products
